Brainstorm Cell Therapeutics Price to Book Ratio

Brainstorm Cell Therapeutics (BCLI) currently reports a P/B ratio of -0.47. That is below the Healthcare sector average of 6.23. Use the charts on this page to explore Brainstorm Cell Therapeutics's P/B ratio history and peer comparisons.

Brainstorm Cell Therapeutics's P/B ratio of -0.47 is lower than the Healthcare sector average of 6.23. That is roughly 107.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/B ratio is a valuation multiple that relates Brainstorm Cell Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At -0.47, BCLI can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/B ratio of -0.47, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 6.23. From there, open related valuation or income-statement pages for Brainstorm Cell Therapeutics, and consider following BCLI for alerts when major investors trade the stock.

Brainstorm Cell Therapeutics is classified in the Healthcare sector. On P/B ratio, it currently shows -0.47 versus a sector average near 6.23. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BCLI with unrelated industries.